|Bid||0.00 x 1300|
|Ask||0.00 x 1300|
|Day's Range||24.81 - 26.89|
|52 Week Range||18.21 - 58.00|
|Beta (5Y Monthly)||-0.58|
|PE Ratio (TTM)||2.96|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.71|
Subscribe to Yahoo Finance Plus to view Fair Value for VIR
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an
With the S&P 500 down over 23% year to date, investors looking for safety are eyeing the healthcare industry. Taylor Carmichael (Vir Biotechnology): Vir Bio is down about 45% in 2022, but it is one of my highest-confidence positions in healthcare right now. When the Food and Drug Administration gave Vir -- and its partner, GlaxoSmithKline -- an Emergency Use Authorization (EUA) for its COVID-19 treatment sotrovimab (trademark Xevudy), demand for the drug skyrocketed.